Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 35Multiple Myeloma 31Lymphoma, Non-Hodgkin 29Burkitt Lymphoma 29Lymphoma 27Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Recurrence 23Hematologic Neoplasms 22Lymphoma, B-Cell 21Lymphoma, Follicular 20Melanoma 16Ovarian Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Neoplasm Metastasis 14Leukemia 14Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Lymphoma, T-Cell, Peripheral 9

Interventions

Temozolomide 2venetoclax 1etoposide phosphate 1Vincristine 1Thiotepa 1Therapeutics 1Telemedicine 1Tamoxifen 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Patient Navigation 1Mesna 1Isotretinoin 1Interviews as Topic 1Immunotherapy, Adoptive 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Genetic Testing 1Filgrastim 1Etoposide 1Early Intervention, Educational 1Drug Therapy 1Cytarabine 1Cyclophosphamide 1Cisplatin 1Celecoxib 1Carboplatin 1Blood Specimen Collection 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pyloric Stenosis, Hypertrophic × Cyclophosphamide × Clear all
NCT06942039 2026-02-27

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

C17 Council

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Medulloblastoma, Neuroblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡